Anti‐Parkinsonian and anti‐dyskinetic profiles of two novel potent and selective nociceptin/orphanin FQ receptor agonists

Abstract

NOP receptor stimulation can provide significant albeit mild anti-dyskinetic effect at doses not causing sedation. The therapeutic window, however, varies across compounds. AT-403 could be a potent and selective tool to investigate the role of NOP receptors in vivo.